Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT03763149 |
| Title | A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Innovent Biologics (Suzhou) Co. Ltd. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| START Midwest | Grand Rapids | Michigan | 49546 | United States | Details | |
| Thomas Jefferson Univerity | Philadelphia | Pennsylvania | 19107 | United States | Details | |
| MD Anderson Cancer Center | Houston | Texas | 77030 | United States | Details | |
| START (South Texas Accelerated Research Therapeutics, LLC) | San Antonio | Texas | 78229 | United States | Details |